ANTIMULLERIAN HORMONE SERUM CONCENTRATIONS IN NORMOOVULATORY AND ANOVULATORY WOMEN OF REPRODUCTIVE AGE
Ariana K Jawad * and Mahabad S Ali **
* Maternity Teaching Hospital, Erbil.
Submitted: 24/12/2012; Accepted: 21/7/2013; Published 1/12/2013
DOI Link: https://doi.org/10.17656/jsmc.10040
Anti-Mullerian hormone (AMH), produced by growing pre-antral and early antral ovarian follicles, has been shown to be a useful marker for ovarian ageing. Serum AMH concentrations are elevated during reproductive life in anovulatory women, especially in those patients exhibiting polycystic ovaries (PCO) and have been implicated in the pathogenesis of polycystic ovary syndrome (PCOS).
The aim of our study is to compare the AMH concentrations in anovulatory women with normoovulatory women of similar age.
Patients and Methods
The study included 70 anovulatory normogonadotrophic women (50 cases with PCOS and 20 cases with Non-PCOS anovulatory women) and 30 cases control group (normal ovulatory women). PCOS patients was diagnosed according to the Rotterdam definition, Serum AMH was measured with a second-generation immunoassay in both groups.
Mean AMH level in anovulatory group was 2.22 ng/ml (0.6-4.10) and for control group was 6.11 (0.10- 19.00), there was significant difference in AMH, LH and testosterone level between patients and control group, difference also significant in AMH level between PCOS and non-PCOS subgroup. There was negative correlation between age of the women and AMH level both in control and patient group.
Serum AMH concentrations are elevated in anovulatory, especially in those patients exhibiting PCOS.
AMH, Anovulatory, Ovulatory, Reproductive age.
1- Rey R, Lukas-Croisier C, Lasala C, Bedecarras P. AMH/MIS: what we know already about the gene, the protein and its regulation. Mol Cell Endocrinol. 2003;211:21–31.
2- Itman C, Mendis S, Barakat B & Loveland LK All in the family: TGF-β family action in testis development. Reproduction .2006;132, 233–236.
3- Knight PG & Glister C TGF-β superfamily members and ovarian follicle development. Reproduction.2006; 132 191–206.
4- Cate RL, Donahoe RK & MacLauglin DT Müllerian-inhibiting substance. In Peptide Growth Factors and their Receptors II, 1990 vol 95, pp 179–210.
5- Pepinsky RB, Sinclair LK, Chow EP, Mattaliano RJ, Manganaro TF, Donahoe PK & Cate RL Proteolytic processing of Müllerian inhibiting substance produces a
transforming growth factor-β-like fragment. Journal of Biological Chemistry. 1988; 263 18961–18964.
6- Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, et al. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004;10:77–83.
7- Pellatt L, Hanna L, Brincat M,Galea R, Brain H, Whitehead S & Mason HD a Granulosa cell production of anti-Müllerian hormone (AMH) is increased in the polycystic ovary. Journal of Clinical Endocrinology and Metabolism.2007;90 240–245.
8- Munsterberg A & Lovell-Badge R Expression of the mouse anti-Müllerian hormone gene suggests a role in both male and female sexual differentiation. Development. 1991 ; 113 613–624.
9- De Vet A, Laven JS, de Jong FH, Themmen APN & Fauser BC Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertility and Sterility. 2002;77 357–362.
10- Burger HG, Dudley EC, Hopper JL, Groome N, Guthrie JR, Green A & Dennerstein L Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. Journal of Clinical Endocrinology and Metabolism. 1999; 84 4025–4030.
11- Bath LE, Wallace WH, Shaw MP, Fitzpatrick C & Anderson RA Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. Human Reproduction. 2003; 18 2368–2374.
12- Seifer DB, MacLaughlin DT, Christian BP, Feng B & Shelden RM Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertility and Sterility. 2002;77 468–471.
13- van Rooij IA, Broekmans FJ, te Velde ER, Fauser BC, Bancsi LF, de Jong FH & Themmen APN Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Human Reproduction. 2002; 17 3065–3071.
14- Franks S Polycystic ovary syndrome. New England Journal of Medicine1995;. 333 853–861.
15-Vendola KA, Zhou J, Adesanya OO, Weil SJ, Bondy CA Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest. 1998 ; 101:2622–2629 .
16- Lockwood GM, Muttukrishna S, Groome NP, Matthews DR, Ledger WL Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: a possible mechanism regulating emergence of the dominant follicle. J ClinEndocrinol Metab. 1998 ; 83:1730–1735.
17- Chavez-Ross A, Franks S, Mason HD, Hardy K, Stark J Modelling the control of ovulation and polycystic ovary syndrome. J Math Biol. 1997 ;36:95–118.
18- Jakimiuk AJ, Weitsman SR, Navab A, Magoffin DA 2001 Luteinizing hormone.
19- Visser JA, de Jong FH, Laven JS, Themmen AP. Anti-Mullerian hormone: a new marker for ovarian function. Reproduction. 2006;131:1–9.
20- Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003;88:5957–62
21-Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab. 2004;89:318–23.
22- Fallat ME, Siow Y, Marra M, Cook C, Carrillo A. Mullerian-inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis. Fertil Steril. 1997;67:962–5.
23- Mulders AG, Laven JS, Eijkemans MJ, de Jong FH, Themmen AP, Fauser BC. Changes in anti-Mullerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility. Hum Reprod. 2004;19:2036–42.
24- Cook CL, Siow Y, Brenner AG, Fallat ME. Relationship between serum mullerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril. 2002;77:141–6.
25- Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, and Dewailly D Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome:relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003 ; 88: 5957-5962.
26- Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod. 2005 Jul;20(7):1820-6. Epub 2005 Mar 31.
27- Park AS, Lawson MA, Chuan SS, Oberfield SE, Hoeger KM, Witchel SF, Chang RJ.Serum anti-mullerian hormone concentrations are elevated in oligomenorrheic girls without evidence of hyperandrogenism. J Clin Endocrinol Metab. 2010 Apr;95(4):1786-92. Epub 2010 Feb 11.